Tan, Yue
Shan, Lingling
Zhao, Liping
Deng, Biping
Ling, Zhuojun
Zhang, Yanlei
Peng, Shuixiu
Xu, Jinlong
Duan, Jiajia
Wang, Zelin
Yu, Xinjian
Zheng, Qinlong
Xu, Xiuwen
Tian, Zhenglong
Zhang, Yibing
Zhang, Jiecheng
Chang, Alex H.
Feng, Xiaoming
Pan, Jing
Article History
Received: 19 January 2023
Accepted: 16 March 2023
First Online: 5 April 2023
Declarations
:
: The Institutional Review Board in Beijing Gobroad Boren Hospital gave its approval to the study. All participants in this clinical trial provided voluntary consent form.
: Written informed voluntary consent form was obtained from the subjects for publication of this study.
: AHC is a founding member of Shanghai YaKe Biotechnology Ltd., a biotechnology company focused on research and development of tumor cellular immunotherapy. YZ and SP are also employees of Shanghai YaKe Biotechnology Ltd. The other authors declare no conflict of interest.